ARTICLE | Emerging Company Profile
T-knife: creating TCR factories with transgenic mice
With €66M series A, T-knife to bring four TCR therapies into the clinic by 2022
August 6, 2020 11:30 AM UTC
Armed with a €66 million ($78.2 million) series A round, T-knife emerged from stealth Thursday with plans to bring four TCR therapies into clinical testing by 2022 using a transgenic mouse platform designed to generate human, high affinity TCRs.
The Berlin-based company spun out of the Max-Delbrück Center for Molecular Medicine in 2018 with €8 million in seed funding from founding investors Andera Partners and Boehringer Ingelheim Venture Fund and IP covering its humanized TCR mouse technology...